Viking Global Investors LP Biogen Inc. Transaction History

Viking Global Investors LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2017 Aug 14, 2017	SELL	N/A	-688,765 Closed	0 $0
Q1 2017 May 15, 2017	SELL	N/A	-1,230,047 Reduced 64.1%	688,765 $188 Million
Q4 2016 Feb 14, 2017	SELL	N/A	-267,524 Reduced 12.24%	1,918,812 $544 Million
Q3 2016 Nov 14, 2016	SELL	N/A	-1,024,171 Reduced 31.9%	2,186,336 $684 Million
Q2 2016 Aug 15, 2016	BUY	N/A	2,979,560 Added 1290.15%	3,210,507 $776 Million
Q1 2016 May 16, 2016	SELL	N/A	-137,917 Reduced 37.39%	230,947 $60.1 Million
Q4 2015 Feb 16, 2016	BUY	N/A	368,864 New	368,864 $113 Million
Q3 2015 Nov 16, 2015	SELL	N/A	-513,444 Closed	0 $0
Q2 2015 Aug 14, 2015	BUY	N/A	513,444 New	513,444 $207 Million
Q2 2014 Aug 14, 2014	SELL	N/A	-388,900 Closed	0 $0
Q1 2014 May 15, 2014	BUY	N/A	388,900 New	388,900 $119 Million
Q4 2013 Feb 14, 2014	SELL	N/A	-290,345 Closed	0 $0
Q3 2013 Nov 14, 2013	SELL	N/A	-675,943 Reduced 69.95%	290,345 $69.9 Million
Q2 2013 Aug 14, 2013	BUY	N/A	966,288	966,288 $208 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.